Given the prominent role of MYCN in the genesis of aggressive pediatric tumors, we sought to identify existing therapeutics that could be useful to target MYCN indirectly, using neuroblastoma as a paradigm of a pediatric tumor that exhibits both clinical and experimental evidence of dependence and addiction to MYCN overexpression. Here, MYCN is linked to neoplasm.